Based on 5 Wall Street analysts offering 12 month price targets for Swedish Orphan Biovitrum AB in the last 3 months. The average price target is kr345.00 with a high forecast of kr400.00 and a low forecast of kr275.00. The average price target represents a 11.15% change from the last price of kr310.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"252":"kr252","401":"kr401","289.25":"kr289.3","326.5":"kr326.5","363.75":"kr363.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr400.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr345.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr275.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[252,289.25,326.5,363.75,401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,312.34,319.0830769230769,325.82615384615383,332.5692307692307,339.3123076923077,346.0553846153846,352.79846153846154,359.54153846153844,366.2846153846154,373.0276923076923,379.77076923076925,386.51384615384615,393.25692307692304,{"y":400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,312.34,314.85230769230765,317.3646153846154,319.87692307692305,322.3892307692308,324.90153846153845,327.4138461538461,329.92615384615385,332.4384615384615,334.9507692307692,337.4630769230769,339.9753846153846,342.4876923076923,{"y":345,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,312.34,309.4676923076923,306.5953846153846,303.7230769230769,300.85076923076923,297.97846153846154,295.1061538461538,292.2338461538461,289.36153846153843,286.48923076923074,283.61692307692306,280.7446153846154,277.8723076923077,{"y":275,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":260.32,"date":1702598400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.48,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.79,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.33,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.8,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.6,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":274.6,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.6,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.99,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":333.19,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":312.34,"date":1733443200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr400.00

Average Price Targetkr345.00

Lowest Price Targetkr275.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Reiterated

12/11/24

Reiterated

10/28/24

Reiterated

10/28/24

Reiterated

10/25/24

Reiterated

10/25/24

xxxxxxxxxxxxx

Charlie Mabbutt

Morgan Stanley

kr330→kr325

Buy

4.70%

Upside

Reiterated

02/13/24

Swedish Orphan Bio (SOBI:SS) (SWTUY) PT Lowered to SEK325 at Morgan StanleyMorgan Stanley analyst Charles Mabbutt lowered the price target on Swedish Orphan Bio (SOBI:SS) (OTC: SWTUY) to SEK325.00 (from SEK330.00) while maintaining a Overweight rating.

Best Analysts Covering Swedish Orphan Biovitrum AB

Which Analyst Should I Follow If I Want to Buy GB:0MTD and Sell After:

1 Month

xxx

Success Rate

7/10 ratings generated profit

Average Return

+2.66%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +2.66% per trade.

3 Months

xxx

Success Rate

8/13 ratings generated profit

Average Return

+2.92%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +2.92% per trade.

1 Year

Alistair CampbellRBC Capital

Success Rate

10/13 ratings generated profit

Average Return

+17.70%

reiterated a buy rating 11 days ago

Copying Alistair Campbell's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +17.70% per trade.

2 Years

xxx

Success Rate

11/13 ratings generated profit

Average Return

+20.90%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +20.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0MTD Analyst Recommendation Trends

Rating

Aug 24

Sep 24

Oct 24

Nov 24

Dec 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0MTD has received 3 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. 0MTD average Analyst price target in the past 3 months is kr345.00.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0MTD Financial Forecast

0MTD Earnings Forecast

Next quarter’s earnings estimate for 0MTD is kr2.88 with a range of kr1.78 to kr4.10. The previous quarter’s EPS was kr4.27. 0MTD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.82% of the time in the same period. In the last calendar year 0MTD has Outperformed its overall industry.

0MTD Sales Forecast

Next quarter’s sales forecast for 0MTD is kr6.85B with a range of kr6.39B to kr7.17B. The previous quarter’s sales results were kr6.89B. 0MTD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.21% of the time in the same period. In the last calendar year 0MTD has Outperformed its overall industry.

0MTD Stock Forecast FAQ

What is GB:0MTD’s average 12-month price target, according to analysts?

Based on analyst ratings, Swedish Orphan Biovitrum AB’s 12-month average price target is kr345.00.

What is GB:0MTD’s upside potential, based on the analysts’ average price target?

Swedish Orphan Biovitrum AB has 11.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Swedish Orphan Biovitrum AB a Buy, Sell or Hold?

Swedish Orphan Biovitrum AB has a consensus rating of Hold, which is based on 2 buy ratings, 2 hold ratings and 1 sell ratings.

What is Swedish Orphan Biovitrum AB’s share price target?

The average share price target for Swedish Orphan Biovitrum AB is kr345.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr400.00 ,and the lowest forecast is kr275.00. The average share price target represents 11.15% Increase from the current price of kr310.4.

What do analysts say about Swedish Orphan Biovitrum AB?

Swedish Orphan Biovitrum AB’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Swedish Orphan Biovitrum AB?

To buy shares of GB:0MTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Swedish Orphan Biovitrum AB (0MTD) Share Forecast & Price Target

0MTD Analyst Ratings

0MTD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Swedish Orphan Biovitrum AB

0MTD Analyst Recommendation Trends

0MTD Financial Forecast

0MTD Earnings Forecast

0MTD Sales Forecast

0MTD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts